| |
Abbvie HCV Drug Development Program
|
| |
| |
Abbvie is currently in a large phase 3 trials program, its expected that by June 2014 Abbvie will submit to the FDA a New drug approval application for this new HCV IFN-free regimen, standard procedure for new drug approvals......Their phase 3 study regimen is IFN-free & contains their potent protease ABT450/r + their NS5A ABT267 + their non-nuc ABT33 with or without Rbv see phase 2 results immediately below
EASL: SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/- RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY - (04/25/13)
IAS: SAFETY OF RIBAVIRIN-CONTAINING REGIMENS OF ABT-450/r, ABT-333, AND ABT-267 FOR THE TREATMENT OF HCV GENOTYPE 1 INFECTION AND EFFICACY IN SUBJECTS WITH RIBAVIRIN DOSE REDUCTIONS - (07/03/13)
INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/- RIBAVIRIN ACHIEVE HIGH SVR12 AND SVR24 RATES IN PATIENTS WITH CHRONIC HCV GENOTYPE 1b - (06/09/13)
Initial Antiviral Activity of the HCV NS3 Protease Inhibitor ABT-450 When Given with Low-dose Ritonavir as 3-Day Monotherapy: Preliminary Results of Study M11-602 in Genotype 1 (GT1) HCV-infected Treatment-na夫e Subjects
http://natap.org/2010/AASLD/AASLD_52.htm
Boosted ABT-450/r HCV Protease 3-Day Monotherapy
www.natap.org/2011/HCV/040411_03.htm
Safety and Antiviral Activity of ABT-267, a Novel NS5A Inhibitor, During 3-Day Monotherapy: First Study in HCV Genotype-1 (GT1)-Infected Treatment-Na夫e Subjects
http://www.natap.org/2012/EASL/EASL_64.htm
4-Week Virologic Response and Safety of ABT-450 Given with Low-dose Ritonavir (ABT-450/r) First As 3-Day Monotherapy Then in Combination with Pegylated Interferon Alpha-2a and Ribavirin (SOC) in Genotype 1 (GT1) HCV-infected Treatment-na夫e Subjects
http://www.natap.org/2010/AASLD/AASLD_10.htm
RISK OF VIROLOGIC RELAPSE IN HEPATITIS C, GENOTYPE 1-INFECTED SUBJECTS AFTER 8, 12, OR 24 WEEKS OF TREATMENT WITH ABT-450/r + ABT-267 + ABT-333 + RBV: IDENTIFYING OPTIMAL TREATMENT DURATION
http://www.natap.org/2013/CROI/croi_06.htm
A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-267 and With and Without Ribavirin (RBV) in Treatment-Na夫e Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
12-Week Effiacy and Safety of ABT-072 or ABT-333 with Pegylated Interferon + Ribavirin, Following 3-Day Monotherapy in Genotype 1 HCV-Infected Treatment-Na夫e Subjects
http://www.natap.org/2011/APSL/APSL_02.htm
ABT-450/ritonavir (ABT-450/r) Combined With Pegylated Interferon Alpha-2a/Ribavirin (P/R) After 3-Day Monotherapy in HCV Genotype 1 (GT1)-Infected Treatment-Na夫e Subjects: 12-Week Sustained Virologic Response (SVR12) and Safety Results
http://www.natap.org/2012/EASL/EASL_74.htm
EASL/2011: Genotypic and Phenotypic Characterization of NS3 Variants Selected in HCV-Infected Patients Treated with ABT-450 - (04/05/11)
|
|
| |
| |
|
|
|
